United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets.
| Revenue (Most Recent Fiscal Year) | $3.18B |
| Net Income (Most Recent Fiscal Year) | $1.33B |
| PE Ratio (Current Year Earnings Estimate) | 20.41 |
| PE Ratio (Trailing 12 Months) | 20.28 |
| PEG Ratio (Long Term Growth Estimate) | 1.78 |
| Price to Sales Ratio (Trailing 12 Months) | 7.36 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.95 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 16.66 |
| Pre-Tax Margin (Trailing 12 Months) | 50.75% |
| Net Margin (Trailing 12 Months) | 40.62% |
| Return on Equity (Trailing 12 Months) | 19.24% |
| Return on Assets (Trailing 12 Months) | 17.25% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.79 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.50 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 2.41 |
| Book Value per Share (Most Recent Fiscal Quarter) | $164.81 |
| Earnings per Share (Most Recent Fiscal Quarter) | $5.82 |
| Earnings per Share (Most Recent Fiscal Year) | $27.86 |
| Diluted Earnings per Share (Trailing 12 Months) | $27.09 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 42.45M |
| Free Float | 38.80M |
| Market Capitalization | $23.32B |
| Average Volume (Last 20 Days) | 0.45M |
| Beta (Past 60 Months) | 0.57 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 94.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |